The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia
Biogen Inc.
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease
Cognitive health the ability to think clearly, to learn and to remember is an indicator of brain health and important to performing daily activities
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI).
(2)
The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma
Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA
1,2,3,4
Biogen remains committed to exploring the potential of SPINRAZA to optimize outcomes for patients with SMA
CAMBRIDGE, Mass., Jan. 08, 2021(Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safety of SPINRAZA (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma
Biogen Inc.
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma
Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA
1,2,3,4
Biogen remains committed to exploring the potential of SPINRAZA to optimize outcomes for patients with SMA
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safet